PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Sells $44,037.90 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 879 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the sale, the chief accounting officer now owns 63,442 shares of the company’s stock, valued at $3,178,444.20. This represents a 1.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Tuesday, January 7th, Christine Marie Utter sold 1,291 shares of PTC Therapeutics stock. The shares were sold at an average price of $45.34, for a total value of $58,533.94.
• On Monday, December 2nd, Christine Marie Utter sold 17,800 shares of PTC Therapeutics stock. The stock was sold at an average price of $51.77, for a total transaction of $921,506.00.

PTC Therapeutics Trading Up 0.6 %

Shares of NASDAQ PTCT traded up $0.31 during midday trading on Friday, reaching $50.69. The company had a trading volume of 423,037 shares, compared to its average volume of 686,683. The stock has a market cap of $3.91 billion, a P/E ratio of -8.53 and a beta of 0.62. PTC Therapeutics, Inc. has a 1 year low of $24.00 and a 1 year high of $54.16. The business’s 50-day simple moving average is $46.58 and its 200 day simple moving average is $41.35.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp increased its holdings in PTC Therapeutics by 132.2% in the 4th quarter. Mackenzie Financial Corp now owns 22,776 shares of the biopharmaceutical company’s stock worth $1,028,000 after buying an additional 12,967 shares during the period. Toronto Dominion Bank purchased a new stake in shares of PTC Therapeutics in the fourth quarter worth about $148,363,000. GF Fund Management CO. LTD. acquired a new stake in PTC Therapeutics during the fourth quarter worth about $73,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in PTC Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,251 shares of the biopharmaceutical company’s stock valued at $7,234,000 after acquiring an additional 26,274 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in PTC Therapeutics in the fourth quarter valued at approximately $7,037,000.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Morgan Stanley upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $45.00 to $67.00 in a report on Friday, December 13th. StockNews.com downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. UBS Group upped their target price on PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Citigroup lifted their price target on PTC Therapeutics from $32.00 to $45.00 and gave the company a “sell” rating in a report on Wednesday, February 12th. Finally, Robert W. Baird upped their price objective on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Three research analysts have rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $58.85.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.